CD274 and neoplasm: Genetic and proteomic analyses revealed that CD38 is upregulated in response to a re-invigorated immune response resulting from treatment with PD(L)-1 blocking antibodies, namely through all-trans retinoic acid (ATRA) and a type I interferon response within the tumor.